Fig. 6: Multidose of ATVCD98hc6.8:DNP variants in CD98hcmu/hu KI mice accumulate in brain without impacting circulating cells.
From: CD98hc is a target for brain delivery of biotherapeutics
a, c Plasma PK of mono- and biATVCD98hc6.8:DNP (170 nM KD) with (EF−) and without (EF+) mutations to mitigate FcγR binding after 5 weekly IV doses (50 mg/kg). Plasma concentrations were assessed at 30 min after each dose (Cmax) and 24 h before the next dose (Ctrough). Two-way ANOVA. b, d Concentrations of ATVCD98hc:DNP variants in brain 24 h after the final dose. One-way ANOVA ****p < 0.0001. See Supplementary Table 6 for exact p values. e–j Circulating cell counts for monocytes (e, h), lymphocytes (f, i) and reticulocytes (g, j) as measured by complete blood count 24 h after the final dose. Cell numbers compared with a one-way ANOVA. a–j All graphs display n = 4–5/group (see Source Data for exact n/group), mean ± SEM. Source data are provided as a Source Data file.
